ArticleACS omega2024
CBD-Loaded Nanostructured Lipid Carriers: Optimization, Characterization, and Stability.
Article in ACS omega, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed.
- Nose-to-brain administration of cannabidiol-loaded polymeric micelles improves the core behavioral symptoms of autism spectrum disorder.Bioactive materials · 2026Article
- Effect of Piperine Codelivery on the Oral Bioavailability of Cannabidiol: Insights fromJournal of agricultural and food chemistry · 2026Article
- Lipid Nanoparticles with Stiripentol and Cannabidiol Oil: From Rational Optimization to Preclinical Characterization.Pharmaceutics · 2026Article
- Effect of Microfluidization Technique on the Physicochemical Characteristics of Cannabidiol Nanoemulsions.Nanomaterials (Basel, Switzerland) · 2026Article
- Exploring the therapeutic potential of cannabidiol in soft tissue wound healing: Delivery strategies and anti-inflammatory pathways.Acta pharmaceutica Sinica. B · 2026Review
- Solid Pro-Nano Lipid Oral Formulations for Cannabidiol (CBD).Pharmaceutics · 2026Article
- Nanostructured Lipid Carrier-Gels for Wound Healing: A Narrative Review of Formulation Strategies, Mechanisms, and Translational Potential.Nanotechnology, science and applications · 2026Review
- Cannabidiol-based lipid nanocarriers with analgesic activity.Scientific reports · 2025Article
- From Screening to a Nanotechnological Platform: Cannabidiol-Chemotherapy Co-Loaded Lipid Nanocapsules for Glioblastoma Multiforme Treatment.Pharmaceutics · 2025Article
- Preparation of Green Tea Polyphenol-Loaded Diacylglycerol Nanostructured Lipid Carrier Hydrogels and Their Activities Related to Skin Protection.Materials (Basel, Switzerland) · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cannabidiol (CBD) has demonstrated its potential to enhance depression treatment through various biological pathways. However, the application potential of CBD is significantly impeded by its polymorphic nature, limited water solubility, and hepatic first-pass metabolism. To improve chemical stability and water solubility, nanostructured lipid carriers loaded with CBD (CBD-NLCs) were developed using a hot-melt emulsification method and optimized by response surface methodology (RSM). The process parameters were optimized using a four-factor and three-level Box-Behnken experimental design consisting of 29 experiments. The CBD-NLCs were formulated and characterized, demonstrating desirable properties, including a mean particle size of 54.33 nm, a PDI value of 0.118, a zeta potential of -29.7 mV, and an impressive encapsulation efficiency rate of 87.58%. The nanoparticles were found to possess an approximately spherical shape, as revealed by scanning and transmission electron microscopy. The stability studies have demonstrated that CBD-NLCs effectively mitigated the photodegradation of CBD and exhibited a stable behavior for 42 days when stored. The CBD-NLCs displayed a biphasic release profile characterized by an initial burst release (over 50% of CBD released within 20 min) followed by a subsequent gradual and sustained release, aligned with first-order kinetics and Fickian diffusion. These findings demonstrate the potential suitability of this formulation as a carrier for CBD in food fortification and pharmaceutical applications.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.